Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

TELESTA THERAPEUTICS INC > lies or creative wording??
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by kristian7on Oct 26, 2016 8:51am
191 Views
Post# 25386488

RE:RE:RE:RE:lies or creative wording??

RE:RE:RE:RE:lies or creative wording??

ProMetic's Plasminogen Meets Primary And Secondary End Points In Pivotal Phase 2/3 Trial

Wednesday, October 26, 2016

 

ProMetic's plasminogen meets primary and secondary end points in pivotal Phase 2/3 trial

06:30 EDT Wednesday, October 26, 2016


  • *** 100% success rate on meeting clinical trial's primary end points required for Accelerated Approval Regulatory Pathway
  •  
  • *** 100% clinical response rate with healing of lesions within weeks of treatment
  •  
  • *** Successful pre-BLA meeting held with FDA
  •  
  • *** ProMetic to commence filing plasminogen BLA modules with the FDA as planned in coming weeks

Read more at https://www.stockhouse.com/companies/bullboard?symbol=t.pli&postid=25386255#7f50ym3dEquKAG67.99
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities